Jaguar Animal Health (NASDAQ:JAGX) Upgraded to Hold at Wall Street Zen

Jaguar Animal Health (NASDAQ:JAGX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Jaguar Animal Health Stock Down 16.1%

JAGX opened at $2.91 on Friday. The company has a debt-to-equity ratio of 4.08, a quick ratio of 0.29 and a current ratio of 0.50. Jaguar Animal Health has a fifty-two week low of $2.53 and a fifty-two week high of $171.50. The firm’s fifty day moving average is $10.82 and its 200 day moving average is $27.13. The stock has a market cap of $1.08 million, a price-to-earnings ratio of 0.00 and a beta of 0.01.

Jaguar Animal Health (NASDAQ:JAGX) last released its earnings results on Wednesday, May 20th. The biotechnology company reported ($13.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($149.10) by $135.50. Jaguar Animal Health had a negative net margin of 169.04% and a negative return on equity of 1,194.94%. The company had revenue of $20.27 million for the quarter, compared to analysts’ expectations of $4.21 million.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.